Eli Lilly & Co. vs. Viking Therapeutics, Inc
Eli Lilly & Co. (LLY) comes out ahead, leading on 4 of 6 compared factors.
Size & Scale
| LLY | VKTX | |
|---|---|---|
| Market Cap | $994.90 billion | $3.91 billion |
| Revenue (TTM) | $65.18 billion | — |
| Net Income (TTM) | $20.64 billion | $-534,796,000 |
LLY leads on 3 of 3 size & scale factors.
Valuation
| LLY | VKTX | |
|---|---|---|
| P/E Ratio | 50.97 | — |
| Price / Book | 37.49 | 9.57 |
| Price / Sales | 15.26 | — |
VKTX leads on 1 of 1 valuation factors.
Profitability
| LLY | VKTX | |
|---|---|---|
| Net Margin | 31.67% | — |
| Return on Equity | 77.78% | -130.98% |
LLY leads on 1 of 1 profitability factors.
Dividend
| LLY | VKTX | |
|---|---|---|
| Dividend Yield | 0.59% | — |
| Payout Ratio | 30.15 | — |
LLY and VKTX split the dividend factors evenly.
Risk & Sentiment
| LLY | VKTX | |
|---|---|---|
| Short Interest | 1.29% | 1.14% |
VKTX leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, VKTX overview, VKTX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.